Holen Sie sich die Stockscreener-App
18.56
6.06%
1.06
Handel nachbörslich:
18.56
Schlusskurs vom Vortag:
$17.50
Offen:
$17.51
24-Stunden-Volumen:
557.83K
Relative Volume:
1.24
Marktkapitalisierung:
$1.00B
Einnahmen:
$2.22M
Nettoeinkommen (Verlust:
$-40.51M
KGV:
-14.45
EPS:
-1.2847
Netto-Cashflow:
$-46.53M
1W Leistung:
+11.00%
1M Leistung:
+61.67%
6M Leistung:
+153.21%
1J Leistung:
+0.00%
1-Tages-Spanne:
$17.05
$18.70
1-Wochen-Bereich:
$15.18
$18.70
52-Wochen-Spanne:
$5.14
$29.46
Upstream Bio Inc Stock (UPB) Company Profile
Firmenname
Upstream Bio Inc
Sektor
Branche
Telefon
781-208-2466
Adresse
890 WINTER STREET, SUITE 200, WALTHAM
Vergleichen Sie UPB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
18.56 | 943.41M | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-05 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-05 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-05 | Eingeleitet | TD Cowen | Buy |
| 2024-11-05 | Eingeleitet | William Blair | Outperform |
Upstream Bio Inc Aktie (UPB) Neueste Nachrichten
Ichimoku Cloud Indicates Uncertainty Around Upstream Bio Inc.July 2025 Volume & Reliable Entry Point Alerts - 선데이타임즈
Short interest data insights for Upstream Bio Inc.Quarterly Trade Review & AI Based Buy and Sell Signals - Newser
Upstream Bio Inc. stock momentum explained [Market Growth Review]Weekly Sector Rotation Insights - Newser
Analyzing recovery setups for Upstream Bio Inc. investorsTrade Volume Summary & Daily Stock Trend Watchlist - Newser
Upstream Bio Appoints Stacy Price as Chief Technology Officer - The Globe and Mail
Tools to assess Upstream Bio Inc.’s risk profileFree Community Entry Consensus Trade Ideas - Newser
Real time social sentiment graph for Upstream Bio Inc.Risk Adjusted Trade Signal Screening Tool - Newser
Upstream Bio Inc. stock retracement – recovery analysisFree Reliable Chart-Based Trade Entries - Newser
Comparing Upstream Bio Inc. in custom built stock radarsFree Short Term Buy Zone Stock Alerts - Newser
Real time breakdown of Upstream Bio Inc. stock performanceFree Chart Alert System With Entry Targets - Newser
Analyzing net buyer seller activity in Upstream Bio Inc.Free Conservative Long Term Growth Plans - Newser
Building trade automation scripts for Upstream Bio Inc.Free Real Time Trade Opportunity Alerts - Newser
What makes Upstream Bio Inc. stock price move sharplyForecasting Stock Moves with AI Insights - Newser
How Efficient Is Upstream Bio Inc. at Controlling Operating CostsChart Signal and Short-Term Forecast Tracker - Newser
Upstream Bio Inc. stock momentum explainedFree Investment Strategy With Predictable Gains - Newser
Upstream Bio Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingMachine Learning Intraday Signal Forecast - Newser
Tools to monitor Upstream Bio Inc. recovery probabilityHigh Reward Picks with Tight Risk Control - Newser
Q3 EPS Estimates for Upstream Bio Decreased by William Blair - Defense World
Upstream Bio Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
How to manage a losing position in Upstream Bio Inc.Free Expert Verified Stock Trade Ideas - Newser
How to use a screener to detect Upstream Bio Inc. breakoutsFree Day Trading Signals With High Precision - Newser
Upstream Bio 2025 Q2 Earnings Net Loss Widens Despite Revenue Surge - AInvest
Upstream Bio, Inc. Reports Increased R&D Investments - TipRanks
Upstream Bio (UPB) Q2 R&D Soars 169% - The Globe and Mail
Is it too late to sell Upstream Bio Inc.Low Risk Strategy with Smart Entry Zones - Newser
Key resistance and support levels for Upstream Bio Inc.Free Swing Trade With Risk Management - Newser
Positive Outlook for Upstream Bio, Inc. Driven by Promising Clinical Trial Developments - TipRanks
Optimistic Buy Rating for Upstream Bio, Inc. Driven by Promising Lead Asset and Strong Execution - TipRanks
Upstream Bio's Q2 2025: Can a Robust Cash Position and TSLP Pipeline Sustain Investor Optimism Amid Rising Burn Rates? - AInvest
Upstream Bio Q2 Net Loss Narrows, Revenue Rises - MarketScreener
Upstream Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Upstream Bio's Strategic Momentum in TSLP Inhibition: A Pathway to Redefining Respiratory Disease Treatment? - AInvest
Earnings Flash (UPB) Upstream Bio Posts Q2 Net Loss $0.74 a Share, vs. FactSet Est of $0.61 Loss - MarketScreener
Upstream Bio reports Q2 revenue $937k, consensus $317k - TipRanks
Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress - GlobeNewswire
Upstream Bio Advances 3 Phase 2 Trials for Novel Respiratory Drug, Q3 Data Readout Imminent - Stock Titan
Finanzdaten der Upstream Bio Inc-Aktie (UPB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):